Fabio Macchi is our new Head of Medical and Quality Departments.
We are extremely proud and excited to announce the latest addition to our "…
Carvykti (ciltacabtagene autoleucel), new gene therapy to treat adult patients with multiple myeloma
EMA has recommended a conditional marketing authorisation in the European Union…
Jardiance (empagliflozin)approved for Wider Range of Patients with Heart Failure
The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to…
Kimmtrak (tebentafusp), a monotherapy for the treatment of adult patients with uveal melanoma, a rare type of eye cancer.
EMA has recommended granting a marketing authorisation in the European Union…
Breyanzi (lisocabtagene maraleucel) New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma
EMA has recommended granting a marketing authorisation in the EU for Breyanzi…
Cyltezo(adalimumab-adbm), the First Interchangeable Biosimilar to Humira
The US FDA has approved the first interchangeable biosimilar product to treat…
Trodelvy (sacituzumab govitecan), First-in-class medicine to treat aggressive form of breast cancer
EMA has recommended granting a marketing authorisation in the European Union…
Byooviz (ranibizumab-nuna), First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions
The FDA has approved Byooviz (ranibizumab-nuna) as the first biosimilar to…
Astepro (azelastine hydrochloride nasal spray, 0.15%), nasal antihistamine approved for nonprescription use
The FDA has approved a nasal antihistamine for nonprescription use through a…
Aduhelm (aducanumab), first new Alzheimer's drug in 20 years.
Aduhelm (aducanumab) has been approved by the FDA for the treatment of…